This phase I trial studies the best dose of ibrutinib when given together with pembrolizumab
in treating patients with stage III-IV melanoma that cannot be removed by surgery.
Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune
system attack the cancer, and may interfere with the ability of tumor cells to grow and
spread. Ibrutinib may stop the growth of tumor cells by blocking some of the enzymes needed
for cell growth. Giving pembrolizumab and ibrutinib may work better in treating patients with